MODERNA INC

Moderna’s mRNA breakthrough fuels biotech buzz—stock hits $80, 31 billion cap, and FDA wins boost investor interest amid Fed‑rate hopes.

Moderna’s stock surged 9.2% on July 2 2026 after strong flu vaccine data, pipeline updates, and bullish analyst sentiment—boosting the healthcare sector and driving mRNA investment interest.

Moderna’s steady rise to $72.50 shows 131% gains from last year, driven by a strong mRNA pipeline and solid biotech market momentum.

Moderna’s breakthrough mRNA flu vaccine and hantavirus research boost share price, analyst upgrades, and market optimism for the biotech firm.

Moderna’s share price surged 100% in six months, driven by promising mRNA‑4359 data and a robust pipeline of cancer, influenza, and RSV vaccines.

Moderna’s April 8 bullish momentum and upcoming ESCMID data on its mRNA‑1010 influenza vaccine promise to drive pipeline expansion, regulatory gains, and stock upside.

Moderna’s $50.52 stock faces a turning point: leadership changes and EMA’s COVID‑influenza combo endorsement boost momentum, but a negative P/E and high volatility demand careful investor scrutiny.

Moderna’s mCOMBRIAX gets EU approval as the first combined COVID‑flu mRNA shot, promising single‑dose protection and a new revenue stream for the company.

Moderna’s share price plunged 83% from late 2022 to late 2025, ranking among the worst performers in a flat S&P 500 session while precious metals spiked.

Moderna secures CEPI funding for Phase III influenza vaccine, fast‑tracking its mRNA tech and boosting investor hope amid market volatility.